Arrowhead Pharmaceuticals Valuation Multiples

Arrowhead Pharmaceuticals Overview

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Founded

1989

HQ

Employees

711

Website

arrowheadpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $624M

EBITDA: ($105M)

EV

$9B

Valuation Multiples

Multiples.vc

Start free trial

Arrowhead Pharmaceuticals Financials

Arrowhead Pharmaceuticals reported last 12-month revenue of $624M and negative EBITDA of ($105M).

In the same LTM period, Arrowhead Pharmaceuticals generated $623M in gross profit, ($105M) in EBITDA losses, and had net loss of ($244M).

Arrowhead Pharmaceuticals P&L

In the most recent fiscal year, Arrowhead Pharmaceuticals reported revenue of $829M and EBITDA of $165M.

Arrowhead Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals has current market cap of $10B, and enterprise value of $9B.

Arrowhead Pharmaceuticals' stock price is $69.51.

Arrowhead Pharmaceuticals Valuation Multiples

Arrowhead Pharmaceuticals trades at 14.6x EV/Revenue multiple, and (87.1x) EV/EBITDA.

Arrowhead Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Arrowhead Pharmaceuticals has market cap of $10B and EV of $9B.

Equity research analysts estimate Arrowhead Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Arrowhead Pharmaceuticals has a P/E ratio of (40.0x).

Arrowhead Pharmaceuticals Margins & Growth Rates

Arrowhead Pharmaceuticals' revenue in the last 12 month declined by (39%).

Arrowhead Pharmaceuticals' revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $1.0M for the same period.

Arrowhead Pharmaceuticals' rule of 40 is (125%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Arrowhead Pharmaceuticals' rule of X is (189%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Arrowhead Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Arrowhead Pharmaceuticals M&A Activity

Arrowhead Pharmaceuticals acquired XXX companies to date.

Last acquisition by Arrowhead Pharmaceuticals was on XXXXXXXX, XXXXX. Arrowhead Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Arrowhead Pharmaceuticals Investment Activity

Arrowhead Pharmaceuticals invested in XXX companies to date.

Arrowhead Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Arrowhead Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).